Antisense compositions targeted to &bgr;1-adrenoceptor-specific mRNA and methods of use
US6489307B1 · kind B1 · utility
Assignee
Inventors
Key dates
| Filing date | Jul 11, 2000 |
| Grant date | Dec 3, 2002 |
| Priority date | — |
| Expiry date | Jul 12, 2020 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2310/3181
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Disclosed are antisense oligonucleotide, polynucleotide, and peptide nucleic acid compounds that specifically bind to mammalian mRNA encoding a &bgr;1-adrenoceptor polypeptide and that are useful in the control and/or treatment of cardiac dysfunction, hypertension, hypertrophy, myocardial ischemia, and other cardiovascular diseases in an affected mammal, and preferably, in a human subject. The antisense compounds disclosed herein, and pharmaceutical formulations thereof, provide sustained control of &bgr;1-adrenoceptor expression over prolonged periods, and achieve therapeutic effects from as little as a single dose. Administration of these antisense compositions to approved animal models resulted in a decrease in blood pressure, but no significant change in heart rate. Use of such antisense compositions in the reduction of &bgr;1-adrenoceptor polypeptides in a host cell expressing &bgr;1-adrenoceptor-specific mRNA, and in the preparation of medicaments for treating human and animal diseases, and in particular, hypertension and other cardiac dysfunction is also disclosed.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.